Tan J, et al. - Researchers evaluated the clinicopathological relevance of capillary morphogenesis protein 2 (CMG2) in a cohort of 48 glioma subjects as well as through public glioma databases, and examined the function of CMG2 utilizing glioblastoma (GBM) models in vitro and in vivo. They noted that CMG2 was implicated in the activation of extracellular signal-regulated kinases (ERKs), epithelial–mesenchymal transition (EMT), migration, and invasion in GBM cells. It was concluded that CMG2 functioned as an oncogene in glioma cells and was a potential prognostic biomarker or therapeutic target for the clinical treatment of glioma.